Home
Life Sciences

Sector: Life Sciences

How a patent dispute with 10x helped decimate NanoString’s stock price

Recent $31 million damages award has dealt a further blow to the company's faltering share value

Software, electronics and semiconductors most transacted assets in Q3 2023

The latest AST Patent Deals Report shows assets being transacted by the likes of Huawei and Intel on the sell side, and Philips and Softbank on the buy side

Life Sciences correspondent

Thought leadership from industry experts

Latest updates

EPO Enlarged Board of Appeal confirms use of post-published data to support inventive step

Latest content

Biogen’s European exclusivity boost is silver lining following US Tecfidera disaster

Following a catastrophic loss of exclusivity stateside, the company has received a boost in the EU

12 May 2023

Gilead scores major victory in controversial $1 billion dispute with US government

Delaware jury rules against the federal government in a big-money patent infringement suit being closely watched by policymakers.

11 May 2023

Amgen sues Sandoz as new wave of biosimilars disputes gains momentum

Following a lull in lawsuits, several new biologics have become the subject of litigation in recent months

05 May 2023

Moderna’s ongoing struggles over covid infringement liability have broader implications

The vaccine maker has suffered another setback, but its fight to deflect infringement responsibility to the US government continues

02 May 2023

European Commission proposes unitary SPC as part of mixed bag of pharma IP reforms

Planned change will make UPC more attractive to life sciences companies

28 April 2023

PTAB experts react to discretionary denial reform package

Various provisions in the USPTO’s rulemaking proposal favour patent owners and others lean towards petitioners, yet one thing is certain: chief IP officers must make their voices heard

26 April 2023

Ravgen continues winning streak in big-money patent assertion campaign

Illumina settlement and clean sweep at the PTAB have added to earlier $273 million damages award

26 April 2023

Amgen’s Federal Circuit victory vindicates $13.4 billion Otezla IP acquisition

The company took a calculated risk by paying billions for drug while a slew of patent challenges were ongoing

25 April 2023

The EPO’s latest plausibility decision is good news for applicants and patentees

The Enlarged Board of Appeal's ruling in G2/21 has significant implications for the use of post-filed data

21 April 2023

Patent cliff concerns drive Merck’s $11 billion Prometheus buyout

Deal hoped to stave off investor concerns about expiring patents and diversify product pipeline

20 April 2023

Unlock unlimited access to all IAM content